No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients

Sundin, Mikael; Ringdén, Olle; Sundberg, Berit; Nava, Stefano; Götherström, Cecilia; Blanc, Katarina Le

doi:10.3324/haematol.11446

Cited by 295 publications

(219 citation statements)

References 52 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…All our patients received MSC from unrelated mismatched donors, whereas only four patients of the other series obtained third-party MSC (four patients received MSC at least once from haploidentical donors, twice from HLA-identical Treatment of acute GVHD with MSC M von Bonin et al siblings). Because anti-FCS antibodies with uncertain clinical significance could be detected in patients after receiving MSC that were expanded in vitro using FCS, 20 we decided for safety reasons to replace FCS by platelet lysates. 17 In addition, compared with our series, the MSC dosage tended to be higher with a median of 1 Â 10 6 /kg (range 0.7-9 Â 10 6 per kg) and nine patients received only one or two MSC infusions in our cohort.…”

Section: Discussionmentioning

confidence: 99%

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Bonin

Stölzel

Goedecke

et al. 2008

Bone Marrow Transplant

275

175

View full text Add to dashboard Cite

Mesenchymal stem cells have been shown to mediate immunomodulatory effects. They have been used in patients with steroid-refractory acute GVHD (aGVHD), but their relevance as a therapeutic agent targeting aGVHD has still to be defined. In this case series, we report 13 patients with steroid-refractory aGVHD who received BM-derived MSC expanded in platelet lysatecontaining medium from unrelated HLA disparate donors. MSC were characterized by their morphological, phenotypical and functional properties. All tested preparations suppressed the proliferation of in vitro activated CD4 þ T cells. MSC were transfused at a median dosage of 0.9 Â 10 6 /kg (range 0.6-1.1). The median number of MSC applications was 2 (range 1-5). Only two patients (15%) responded and did not require any further escalation of immunosuppressive therapy. Eleven patients received additional salvage immunosuppressive therapy concomitant to further MSC transfusions, and after 28 days, five of them (45%) showed a response. Four patients (31%) are alive after a median follow-up of 257 days, including one patient who initially responded to MSC treatment. In our patient cohort, response to MSC transfusion was lower than in the series reported earlier. However, our experience supports the potential efficacy of MSC in the treatment of steroid-refractory aGVHD.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Bonin

Stölzel

Goedecke

et al. 2008

Bone Marrow Transplant

275

175

View full text Add to dashboard Cite

show abstract

“…It was shown that a single preparation of 10 8 hMSCs grown under standard conditions in FBS carry with it approximately 7-30 mg of FBS proteins (10). Thus, in view of a clinical GMP production, the use of xenogenic serum is complicated as there is high lot-to-lot variability and it is associated with a risk of transmitting infectious agents and immunizing effects (12,13).…”

Section: List Of Abbreviationsmentioning

confidence: 99%

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

“…14 Thus, MSCs are not intrinsically immunoprivileged. Sundin et al 15 detected no anti-HLA Abs when analyzing 12 GVHD patients after MSC infusion, but confirmatory studies are needed. Patients with acute GVHD are heavily immunosuppressed, but patients with functional immune systems may respond differently and develop multi-specific anti-HLA Abs.…”

Section: Introductionmentioning

confidence: 99%

Stromal cells–are they really useful for GVHD?

Kaipe

Erkers

Sadeghi

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) have immunomodulatory effects and are increasingly being used for the treatment of acute and chronic GVHD. Although they seem immuno-privileged, they induce alloresponses, but the risk of immunization is poorly characterized. After infusion, they first reach the lungs, liver and spleen, and are then difficult to trace. Several mechanisms are involved in stromal cells suppressing alloreactivity, such as induction of regulatory T cells, but whether or not this will also affect leukemic relapse or increase infections is not known. Although several encouraging pilot studies have been published, there have been few prospective randomized trials. There may be a bias in the literature, as negative results are seldom published, and there have been few comparative studies with other immunosuppressive regimens. Most animal models have failed to show any effect on GVHD. Several questions remain to be answered for optimization of stromal cell therapy. Which source is optimal-BM, fat, cord or decidua? Can stromal cells be replaced by exosomes, which culture conditions are most appropriate and at what passage and how frequently should cells be administered? More research is required to move stromal cell therapy forward to become an established treatment for acute and chronic GVHD.

show abstract

No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients

Cited by 295 publications

References 52 publications

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

Stromal cells–are they really useful for GVHD?

Contact Info

Product

Resources

About